RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication
26 oct. 2020 09h00 HE
|
RedHill Biopharma Ltd.
H. pylori eradication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial, with antibiotic resistance a contributing factor. Despite declining...
RedHill Biopharma Announces Publication of Talicia® Pivotal Phase 3 Study Results in Annals of Internal Medicine
05 mai 2020 07h00 HE
|
RedHill Biopharma Ltd.
Talicia® is approved by the U.S. FDA and promoted by RedHill’s U.S. sales force--Abstract discussing Talicia pharmacokinetics and exposure-response presented as ePoster at Digestive Disease Week®...
RedHill Biopharma Strengthens Coverage for Talicia® with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary
28 avr. 2020 07h00 HE
|
RedHill Biopharma Ltd.
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care...
RedHill Biopharma to Host Analyst and Investor Webcast on TALICIA® for H. pylori infection on October 30, 2018
29 oct. 2018 07h00 HE
|
RedHill Biopharma Ltd.
Top-line results from the ERADICATE Hp2 confirmatory Phase III study expected before year-end 2018H. pylori bacterial infection affects over 50% of the adult population worldwide and 30-40% of the...
RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
24 oct. 2018 08h00 HE
|
RedHill Biopharma Ltd.
RedHill will host an Analyst and Investor Webcast on TALICIA® for H. pylori infection on Tuesday, October 30, 2018, at 8:30 a.m. EDTFinal patient assessed for primary endpoint, with top-line results...
RedHill Biopharma Announces Completion of Enrollment for Confirmatory Phase III Study with TALICIA® for H. pylori Infection
04 sept. 2018 07h00 HE
|
RedHill Biopharma Ltd.
Top-line results from the randomized, double-blind confirmatory Phase III study (ERADICATE Hp2 study) with TALICIA® are expected before year’s end The ERADICATE Hp2 study enrolled 455 patients with...
RedHill Biopharma Enrolls 400th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
24 juil. 2018 08h22 HE
|
RedHill Biopharma Ltd.
400 of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA® for H. pylori infection (ERADICATE Hp2)RedHill expects to complete enrollment...